Biogen Inc. (BIIB) Earnings Call Transcript & Summary

July 22, 2021

NASDAQ US Health Care Biotechnology earnings 75 min

Earnings Call Speaker Segments

Mike Hencke

executive
#1

Hello, everyone, and thanks for joining us for Biogen's Q2 2021 earnings call. Before getting started, I'd ask that all of you visit the Investors area of biogen.com, where you can locate the earnings release along with the associated financial tables — this includes our GAAP financial measures as well as a reconciliation between the GAAP and non-GAAP financial measures we'll be covering today. Tables 1 and 2 contain our GAAP financials, while Table 4 provides a reconciliation of our GAAP to non-GAAP financial results. In our view, non-GAAP financial results give a better picture of the ongoing economics of our business and show how we run things internally. We've also put slides up on our website that track with the discussions relating to this call. I want to note that forward-looking statements will be made, and these rest on our present expectations and beliefs. Such statements carry certain risks and uncertainties, and our actual results could differ materially. For more detail, I'd suggest reviewing the risk factors covered in our SEC filings. Joining me today are our Chief Executive Officer, Michel Vounatsos; Dr. Al Sandrock, Head of Research and Development; and our CFO, Mike McDonnell. For the Q&A part of our call, Chirfi Guindo, Head of Global Product Strategy and Commercialization, and Alisha Alaimo, President of our U.S. organization, will also be with us. <<operator_script>> I'll now hand the call over to Michel.

Michel Vounatsos

executive
#2

Hello, everyone, and thanks for being here today. We've gotten through the first half of what is a transformative year for Biogen, making strides throughout our neuroscience portfolio. But before anything else, I want to talk about the confusion and criticism that has arisen regarding the recent approval of ADUHELM. We hear the main concerns being raised by the community, and we're striving to offer more clarity by pursuing the following objectives: looking at every possibility to broaden patient access, including for underserved groups and those facing higher risk because of ethnicity; providing education about the revised label language, which I'll get into; getting our Phase III results published in a peer-reviewed journal and sharing further data to guide clinical practice, such as how ARIA is managed; speeding up the launch of the Phase IV confirmatory study; and making the most of the unique data generation opportunity offered by EMBARK, the longest and most comprehensive longitudinal study ever conducted for an Alzheimer's disease therapy. The clinical data from 8 studies involving over 3,000 patients that backed accelerated approval is something Biogen firmly supports. As the FDA's current chief said publicly earlier this month, ADUHELM received approval appropriately on very solid grounds and was the right thing to do for patients. Let me be clear that Biogen fully supports the integrity of the review process. Dialogue conducted respectfully between industry and regulators is both standard and vital for advancing understanding of the therapeutic data that drives innovation, as was shown more recently by last year's COVID-19 vaccine development programs. In our view, the accelerated approval pathway has already transformed oncology treatment, and it now has the potential to do the same for Alzheimer's disease treatment; we understand the concerns regarding price, and we're dedicated to ensuring the system remains sustainable while maximizing patient access. Absent access, with each day that goes by, we estimate roughly 1,000 Americans transition from the early stage of Alzheimer's into moderate or severe dementia, and as a result, may no longer be suitable for any session of treatment with ADUHELM. That's why we're acting with urgency to engage the community, payers, CMS and policymakers to explore potential innovative approaches, aiming to make sure the price doesn't create access problems for patients. Having said that, I'd like to turn to the fundamentals. Another quarter of solid underlying financial performance that came in above our expectations, the accelerated approval of ADUHELM for people living with Alzheimer's disease, and key readouts across our diversified portfolio. To begin, the accelerated approval of ADUHELM marks the first new therapy for Alzheimer's disease in nearly 20 years. Biogen has a long track record of building new markets and bringing innovative, impactful therapies to patients in need. We pioneered and still hold the market-leading portfolio of therapies for MS. We delivered the first approved and market-leading therapy for SMA. So, with ADUHELM, we now have the first therapy that's been approved to target a defining pathology of Alzheimer's disease, and we think this represents a major opportunity for value creation in the years ahead. To help us successfully carry out our long-term leadership strategy, I'm happy to share that Rachid Izzar is going to lead our newly formed Alzheimer's disease and dementia business unit, and he'll also be joining Biogen's Executive Committee. Right now, Rachid oversees Biogen's intercontinental region as well as our biosimilars business unit. His background spanning many geographies and a global role will benefit us greatly as he works to maximize the impact we can have on the lives of people dealing with this devastating disease. We've observed strong signs of very high initial patient interest in ADUHELM, along with more referrals coming from PCPs to specialists. That said, getting sites up and running is going to take some time. Although certain large centers have indicated they'll hold off for now on giving ADUHELM to patients, plenty of other sites are proceeding with their internal processes, like pharmacy and therapeutics, or P&T committee review, and some are moving faster than we'd initially anticipated. Out of the roughly 900 sites we thought would be ready soon after approval, we estimate that about 325, or 35%, have either finished a P&T review with a positive result or said they won't need a P&T review. We've also noticed some sites making use of external infusion centers when they encounter internal resistance or are waiting for clarity on their facilities' internal process; we still believe that, in line with our clinical trials, most specialists will need confirmation of amyloid beta pathology, whether through PET or CSF, and scheduling and coordinating that also takes time. On the reimbursement side, it's still early, and I'm glad to report that we've seen the first instances of Medicare Advantage plans granting pre-authorization. We welcome CMS's recent opening of a national coverage determination analysis for monoclonal antibodies targeting amyloid beta, ADUHELM included. We think this process will bring added clarity on coverage for Medicare beneficiaries and drive more consistent access across the country. We expect regional Medicare administrative contractors and Medicare Advantage plans to cover our ADUHELM while the NCD analysis is ongoing; we see CMS's quick decision to start the NCD analysis as evidence of the substantial unmet need in Alzheimer's disease and the urgency of clarifying access for patients. In July, we received new label language for ADUHELM clarifying that treatment should begin in patients with mild cognitive impairment due to Alzheimer's disease or mild Alzheimer's dementia. That's the population studied in our clinical trials and where we generated clinical evidence, as stated in Section 14 of the ADUHELM label. This updated language matches our consistent expectation that ADUHELM will be prescribed mainly by specialists for patients in the early stage of Alzheimer's disease. This new information has been warmly embraced by the patient community, as well as by those who prescribe, those who pay, and those who shape policy. Beyond America's borders, we remain in active dialogue with regulatory bodies about the review that is still underway across Europe, Japan and additional markets, and at the same time we keep filing new regulatory submissions across the globe; on top of that, we are chasing early access pathways at every opportunity, among them an early access program and a charge managed access program. We understand that creating an entirely new marketplace for Alzheimer's disease is a task without precedent. And that our journey has only just started, since our goal is to bring ADUHELM and possibly lecanemab to patients everywhere on earth. Our confidence is strong that our teams possess what is needed to carry out a clearly articulated plan focused on securing long-term leadership for Biogen in Alzheimer's disease. Next, during this quarter, our pipeline produced important results at the mid- to late-stage in critical fields, among them depression, stroke and biosimilars. The favorable WATERFALL Phase III study of zuranolone in major depressive disorder represents a major step toward delivering a distinctive possible therapeutic choice to the 17 million patients who suffer from depression within the U.S. by itself. The rapid benefit we saw appearing in as little as 3 days, alongside a distinctive tolerability profile and a 2-week dosing schedule, reinforce our conviction that zuranolone, should it win approval, would become a multibillion-dollar product. We likewise felt great enthusiasm upon seeing favorable data from the Phase IIa study of TMS-007 in acute ischemic stroke.

Michel Vounatsos

executive
#3

Stroke ranks as the number two cause of mortality globally, and survivors can endure permanent brain injury; the trial data gave us strong encouragement, and we promptly proceeded to exercise our option for acquiring TMS-007. If both zuranolone and TMS-007 gain approval, Biogen would occupy a leading role in providing innovative treatments for Alzheimer's disease, the top neurodegenerative condition, depression, among the most prevalent mental health disorders, and stroke, a major source of neurologic disability; beyond those findings, we achieved a favorable Phase III result for our biosimilar that references ACTEMRA. With such favorable outcomes available, we start getting ready for a regulatory submission. Like any organization pursuing cutting-edge science, we likewise encountered disappointments in certain programs, among them our anti-tau antibody for Alzheimer's disease and our ophthalmology gene therapy efforts. Third, we delivered a strong quarter through ongoing solid execution throughout our primary operations in MS, SMA and biosimilars; and we take pleasure in increasing our revenue outlook for the year, about which Mike will speak. Q2 MS revenue overall, factoring in OCREVUS royalties, came to $1.8 billion. Excluding the arrival of TECFIDERA generics within the U.S., our wider MS operation kept showing resilience, registering a 5% rise in patients globally. Such results highlight our capacity for strong execution; we felt quite gratified by ongoing revenue expansion for VUMERITY, which stays the #1 oral MS offering by new prescriptions within the U.S. We view this outcome as evidence of VUMERITY's robust product profile. Considering how the VUMERITY launch has progressed so far, along with anticipated launches outside the U.S., we think VUMERITY may eventually achieve more than $1 billion in yearly sales. We additionally kept funding new prospective treatments aimed at the residual unmet medical needs for — among MS patients. Last week, we disclosed a license and collaboration arrangement with InnoCare concerning orelabrutinib, a novel CNS penetrant Phase II BTK inhibitor intended as a possible therapy for every form of MS; this deal depends on usual closing conditions. Next, SPINRAZA produced $500 million in global revenues during the second quarter. Although SPINRAZA confronts competition within the U.S., worsened by the effects of the COVID-19 pandemic, we took encouragement from seeing SPINRAZA discontinuation keep declining relative to Q1 of this year. U.S. total revenue held steady compared with the preceding quarter. And SPINRAZA kept delivering very strong results beyond the U.S; posting 23% revenue growth relative to Q2 of last year. SPINRAZA stays the leading treatment on the market for SMA. And we support SPINRAZA's demonstrated efficacy along with its well-established safety profile across every type of SMA; indeed, our market research shows that SPINRAZA's perceived efficacy among adults has risen during the past year and surpasses the efficacy perception for therapeutic alternatives, Risdiplam included. Even though SMA is dealing with some short-term rivalry right now, our view is that SPINRAZA will keep expanding across the medium and longer horizons, in America as well as worldwide. That growth should come from the market as a whole getting bigger, the way the drug performs in terms of efficacy and safety across every age group, ongoing generation of data — especially among older individuals — and more geographic reach. Revenue from our biosimilars segment reached $202 million during this quarter. We stay committed to carrying out our plans for the medicines we already sell, but at the same time we're seeking to broaden what we offer, which includes the collaboration we entered into recently with Bio-Thera and a favorable CHMP opinion for the biosimilar we have that references Lucentis. Number four, there are still 2 important Phase III data readouts we expect before 2021 ends. These consist of the Phase III trial of tofersen — possibly the very first therapy aimed at a genetic target for ALS — plus one more Phase III involving zuranolone for major depressive disorder. Because the unmet medical need in ALS is so extraordinary, and because results from the earlier tofersen trial were encouraging, we started an individual compassionate use program not long ago so that tofersen can reach patients with SOD1-ALS whose disease is progressing fastest. When you put all of this together, these steps mark major progress toward our ambition of remaking Biogen — turning it from a company that was formerly centered on MS into one whose foundation is a portfolio of multiple franchises spanning a wide range of neuroscience therapeutic areas. At this point I'd like to hand the call over to Al, who will give a more thorough update regarding how our R&D efforts are advancing.

Alfred Sandrock

executive
#4

Thanks, Michel. First, I want to share some thoughts regarding aducanumab. The accelerated approval for aducanumab has sparked conversations that reflect a wide spectrum of views, including regarding how well it works, the FDA's choice of the accelerated approval pathway, and the regulatory process more broadly. Since June 7, the FDA has issued multiple statements to clarify these matters. As we always do, we look to the FDA as the primary authority on these issues. They are the independent regulatory body tasked with evaluating the data with expertise and impartiality so they can make crucial decisions that could affect millions of individuals. Still, I felt it would be useful to offer our viewpoint on a number of these subjects, including how we interacted with the agency. Our dedicated team's efforts to develop aducanumab make us proud, as does the hope it offers to Alzheimer's disease patients. We take equal pride in the professionalism shown by our team and by the FDA throughout an extremely long process. So we support a formal review of the interactions between FDA and Biogen leading up to aducanumab's approval. Gaining a clearer picture of the facts benefits all parties by ensuring confidence in the therapy as well as in the process through which it received approval. We will give our complete cooperation to the review, while still prioritizing the matters that impact patients. I want to emphasize that it is entirely normal and fitting for scientists and clinicians to examine data from experiments and clinical trials, to debate, and to hold differing views on what the data means. That is precisely how science moves forward, and we embrace these discussions. That said, I want to set the record straight on some inaccurate claims that have circulated lately. To begin, a number of individuals have claimed that every anti-amyloid antibody removes amyloid from the brain. That is simply not true. First-generation anti-amyloid antibodies, including bapineuzumab and solanezumab, lack specificity for aggregated forms of Abeta, or they target soluble monomeric Abeta, while crenezumab, an IgG4, has deficient effector function. Consequently, amyloid is not cleared from the brain by these antibodies. This slide presents amyloid PET imaging findings from peer-reviewed literature on these first-generation antibodies. For crenezumab and solanezumab, there was no meaningful difference versus placebo when it came to amyloid plaque burden. In the Phase III trials, bapineuzumab did demonstrate a significant difference versus placebo, yet this was mostly attributable to an unexplained rise in amyloid plaque burden among those placebo-treated patients in the mild-to-moderate stage of Alzheimer's disease. In our view, this amyloid plaque increase in placebo patients had to be a spurious finding, since we now understand that plaque buildup maxes out by the time patients reach mild cognitive impairment; put simply, nothing shows that the first-generation antibodies against Abeta truly eliminated amyloid plaque. Using the failure of those antibodies as grounds to reject aducanumab has no basis. We've likewise heard claims that every aducanumab result is post hoc, and that too is not accurate. Before any patient entered the Phase III trials, the primary and secondary endpoints were already specified in the protocols and statistical analysis plans. The aducanumab label presents findings on those prespecified endpoints, drawing on data already gathered at the sites by the point when the trials were halted early on March 21, 2019. Others, separately, have argued that ARIA caused unblinding. We went to considerable lengths to make sure the neurologists evaluating clinical outcome measures were unaware of whether ARIA had occurred. One method we used to satisfy ourselves that unblinding did not influence the results was to look at clinical outcomes following the appearance of ARIA. Were ARIA to have compromised blinding, one would expect results after ARIA to shift; this slide demonstrates that results excluding data obtained after ARIA events matched the overall results. We therefore have confidence that unblinding stemming from ARIA did not alter the Phase III trial results for aducanumab. Lastly, certain individuals have suggested that approving aducanumab would stifle development of other Alzheimer's disease drugs. Precedent refutes this claim. A prime illustration is the history of drug approvals for HIV/AIDS, non-Hodgkin's lymphoma and multiple sclerosis, among others. In neurology, the first medicine ever approved for MS came in 1993, when beta interferon gained accelerated approval in the United States. Over the following several years, 2 additional types of beta interferon won approval after controlled clinical trials demonstrated that they slowed disability progression. Currently, more than 20 drugs are approved to treat MS. Every one of them lowers relapse risk, slows disability progression, or does both. All new molecular entities were approved on the basis of randomized controlled clinical trials that continue being run to this day, nearly 30 years after beta interferon's accelerated approval. We think a comparable situation is only now beginning to emerge with Alzheimer's disease. In the years ahead, data will arrive from Phase III trials of several second-generation anti-amyloid antibodies, which can effectively clear amyloid plaque. We will also have results from the post-marketing trial of aducanumab. Such data ought to resolve any remaining uncertainty about the efficacy of this class. Meanwhile, the principal serious risk tied to aducanumab is ARIA. According to Phase III trial data, ARIA, an amyloid-related imaging abnormality, appeared in 41% of patients who received aducanumab 10 milligrams per kilogram and 10% of patients who received placebo. Among patients on aducanumab who developed ARIA, 24% had clinical symptoms. Put differently, roughly 10% of patients treated with the approved aducanumab dose had symptomatic ARIA. Serious symptoms were reported in 0.3% of patients. Alzheimer's disease is 100% fatal. Also, prior to dying, it strips individuals of their very selves. If these further clinical trials verify that drugs of this kind work to decelerate clinical deterioration, as Michel noted, then people without any way to obtain aducanumab might cease to be suitable candidates for care. The aducanumab findings have now been the subject of our conversations for quite a few months. On June 7, aducanumab received approval for use within the United States, and the label lays out the data in a clear summary. What we hope for is that physicians will talk over the advantages and dangers of using aducanumab with those they treat and the people caring for them, grounded in reasoned evaluation and correct details; through various channels, we are making every effort to supply that information to those who prescribe. To begin with, we will keep giving talks at scientific gatherings and releasing analyses drawn from our Phase III aducanumab studies, concentrating on getting the main paper published and spreading further findings to guide clinical practice, which encompasses handling ARIA. Four presentations are slated for the AAIC meeting taking place next week as part of this. Next, we are proceeding urgently to complete the blueprint for the Phase IV controlled post-marketing confirmatory aducanumab trial, which aims to confirm the clinical advantage of aducanumab in Alzheimer's disease. We continue to sort out the specifics and remain in active dialogue with regulatory bodies.

Alfred Sandrock

executive
#5

We want to get this study done as fast as we can, and much earlier than the roughly 9-year post-marketing requirement. Third, the EMBARK long-term extension study gives us a one-of-a-kind chance to generate data. This month alone, we randomized the final participant in that trial, which brings total study enrollment to about 1,700 patients with Alzheimer's disease. Over 2 years, EMBARK will follow patients who received aducanumab previously for as long as about 6.5 years, so it will produce valuable long-term safety and efficacy information on aducanumab. We intend to share the EMBARK baseline data at a medical meeting soon, and that ought to provide key insights into what happens when treatment is interrupted, the longer-term consequences of lowering amyloid plaques, and the possible advantages of staying on therapy. Finally, we intend to launch a real-world observational trial in Alzheimer's disease known as ICARE AD-US, so that we can gather real-world long-term effectiveness and safety data regarding aducanumab; we are likewise assessing other formulations of aducanumab, aiming to boost patient confidence. Last month, we began a Phase I trial looking at bioavailability for a subcutaneous version of aducanumab, and we kept talking with regulators about the right development strategy. And last, we keep moving forward our innovative pipeline of possible Alzheimer's disease therapies. That pipeline features lecanemab, the other anti-amyloid antibody we are working on together with Eisai. The FDA recently granted lecanemab breakthrough therapy designation, and alongside Eisai we are engaging the FDA to find the best regulatory route. We also anticipate the readout from the CLARITY Phase III trial of lecanemab, which is expected next year. Beyond our anti-amyloid efforts, we are going after tau as well, which is the main building block of neurofibrillary tangles, another pathological signature of Alzheimer's disease. Even though it was disappointing to find out that the Phase II trial of gosuranemab in early Alzheimer's disease failed to hit its primary or secondary endpoints, we don't think those findings make tau any less relevant as a possible therapeutic target in Alzheimer's disease. We have halted the BIIB092 program, but we are still developing BIIB080, our antisense oligonucleotide, designed to lower production of every form of tau, inside and outside cells. Phase I trial results are going to be presented at AAIC next week. Beyond Alzheimer's disease, during this quarter we kept advancing a wide neuroscience pipeline, with positive data readouts in depression and stroke, two fields that need innovation. First, neuropsychiatry. Working with Sage, we were pleased to find out that the Phase III WATERFALL trial testing a 50-milligram dose of zuranolone in major depressive disorder met its primary endpoint. Even with the strong placebo effect seen in WATERFALL, 2 weeks of zuranolone treatment produced a statistically significant decrease in depressive symptoms on day 15, measured with the HAM-D-17 scale compared with placebo. Zuranolone also acted quickly, with treatment effects appearing at day 3, 8 and 12. The tolerability picture matched what had been observed before: the majority of treatment-emergent adverse events fell into the mild to moderate range, and no signal emerged regarding heightened suicidal thoughts or actions, nor any withdrawal effects. Our conviction remains that zuranolone — given how quickly it acts, the lasting benefits that follow a 2-week dosing period, and its distinct tolerability — could reshape how depression is treated. Right now, alongside Sage, we are figuring out the best regulatory submission route. The WATERFALL study likewise forms — represents one piece of the broad development effort behind zuranolone, which additionally encompasses the SHORELINE, CORAL and SKYLARK trials, all ongoing. Top line results from CORAL and SHORELINE should arrive in 2021; together with Sage, we are assessing enrollment rates for SKYLARK, and once that assessment wraps up, updates will follow. Positive results also came in from the Phase IIa trial of TMS-007 for acute ischemic stroke. Today's standard of care for ischemic stroke involves thrombolytic agents given within 3 to 4.5 hours of when symptoms begin. Those approved agents additionally bring an intracranial hemorrhage, or ICH, risk that grows as time passes. In the Phase IIa trial of TMS-007, now called BIIB131, dosing occurred 4.5 to 12 hours following stroke symptom onset, averaging 9.5 hours. Symptomatic ICH did not occur in the BIIB131 arm. Relative to placebo, BIIB131 raised the recanalization rate of occluded intracranial arteries, as seen through MR angiography among patients with large vessel strokes. Furthermore, a greater number of patients recovered independent functioning, per the modified Rankin Scale at day 90, versus placebo; these study results encourage us, and we hold hope that BIIB131 might become a next-generation thrombolytic capable of safely lengthening the treatment window after a stroke begins. Our plan is to move BIIB131 into late-stage development at the earliest opportunity. Our MS pipeline also gained strength via a proposed license and collaboration agreement with InnoCare covering a Phase II oral small molecule BTK inhibitor for potentially treating MS. Orelabrutinib, a covalent BTK inhibitor featuring high selectivity and demonstrated CNS penetrants, is presently under investigation in a global placebo-controlled Phase II trial for relapsing-remitting MS. Orelabrutinib's capacity to cross the blood-brain barrier, paired with its high kinase selectivity, sets it apart from other BTK inhibitors now being developed for MS. As we look at the rest of the year, 2 pivotal readouts in ALS and depression still lie ahead. Earlier this month, the 1-year placebo-controlled treatment period of the Phase III tofersen study in SOD1-ALS wrapped up, and the readout should come by this fall. We also recently dosed the first participant in ATLAS, a Phase III tofersen trial launched in clinically presymptomatic SOD1 mutation carriers. We think that intervening at an earlier stage of the illness could offer the greatest chance to decelerate or perhaps postpone the emergence of this awful condition. To sum up, during this quarter our R&D team achieved meaningful strides in moving our pipeline forward. Alongside the accelerated approval for aducanumab, we finished 5 readouts in the mid- to late stage across a number of important therapeutic areas marked by substantial unmet need, among them depression and stroke. Neuroscience as a discipline is moving ahead quickly, and given the investments we have committed to prioritizing genetically validated targets, to deploying biomarkers within early-stage clinical programs, and to building up our human and technological capabilities, we feel we are well positioned to seize the many opportunities this thrilling area of science presents, for the good of patients. At this point I will hand the call to Mike.

Mike McDonnell

executive
#6

Thanks, Al. Like Michel mentioned, we felt really good about how Q2 turned out, since we kept executing at a high level. Competition from TECFIDERA generics here in the U.S. is still something we're up against, and that weighed on our year-over-year financials. That said, going forward, our attention stays squarely on the core business and on rolling out ADUHELM here in the United States. Second quarter total revenue came in at $2.8 billion, which is down 25% compared with the prior year on an actual currency basis and down 26% at constant currency. That decline is due to TECFIDERA facing generic competition, plus about $330 million in revenue recorded during Q2 2020 from a one-time licensing deal involving certain manufacturing-related intellectual property. Even so, it was a positive sign that overall revenue grew 3% versus Q1 2021, with the MS franchise and OCREVUS royalties providing most of that lift. ADUHELM brought in $2 million during the second quarter. If you want details about how the accounting works with Eisai and Neurimmune, please refer to our slides and what we said on our June 8 call. MS revenue, which includes OCREVUS royalties, reached $1.8 billion in the second quarter. Let's now turn to a handful of the products inside MS. Globally, TECFIDERA generated $488 million in the second quarter. On the domestic side, Q2 brought in $178 million, an increase over the previous quarter, which we attribute to seasonal patterns and shipping timing. Regarding TECFIDERA within the U.S., our expectation is that it will continue sliding downward for the rest of the year. Turning to markets abroad, TECFIDERA generated $309 million in the second quarter, representing a 15% gain versus the same period a year ago, driven by 6% growth in underlying patients; we felt good about VUMERITY's ongoing acceleration, which went from $74 million in Q1 to $91 million in Q2. As Michel noted, our belief is that over time VUMERITY has the potential to reach $1 billion in yearly revenue. During Q2, TYSABRI brought in $524 million worldwide, a 21% year-over-year gain, helped by shipping patterns both domestically and abroad. We were encouraged by a 7% rise in the number of patients on TYSABRI globally. In our view, TYSABRI is positioned well to take on a growing role in treating MS. Turning to SMA: SPINRAZA's worldwide revenue for the second quarter came to $500 million, up 1% from a year earlier using actual currency, but down 3% on a constant-currency basis. Stateside, SPINRAZA generated $149 million, a 29% decline compared with the same period last year, reflecting ongoing pressure from competing products. When you look at markets beyond the United States, SPINRAZA sales rose 23% compared with a year earlier, though a portion of that increase came from shipments that arrived sooner than usual. Now let's turn to biosimilars. We posted $202 million in revenue for the second quarter, up 18% year over year in actual currency terms and up 9% on a constant currency basis. We achieved that gain even as pricing pressure kept hurting this part of our business, along with fewer patients starting new therapies and less available clinic capacity because of the COVID-19 pandemic. Despite the ongoing drag from COVID-19, we now rank as the number one supplier of anti-TNF products throughout Europe. For anti-CD20, total revenue reached $440 million in Q2, representing a decline of 8% relative to the equivalent quarter a year ago. RITUXAN's revenue fell roughly 32% year over year, though that was partly balanced out by OCREVUS royalties climbing 23%. Gross margin for the second quarter stood at 83% of revenue, a modest rise from 82% in the previous quarter but below the 89% recorded in Q2 2020. The year-over-year margin decline largely stemmed from lower TECFIDERA and RITUXAN sales, since both carry high margins. On top of that, Q2 2020 contained roughly $330 million of revenue from a onetime licensing arrangement for certain manufacturing-related intellectual property, which carried a 100% gross margin. Now let's move to expenses and the balance sheet. During the second quarter, our non-GAAP R&D expenses came to $585 million. Roughly $50 million of that amount consisted of upfront payments for three business development agreements. The first was with Bio-Thera and involves biosimilars. The second, with Capsigen, centers on gene therapy. The third, with Ginkgo, is meant to create an innovative manufacturing platform for gene therapy. Non-GAAP SG&A in Q2 totaled $635 million, and approximately $115 million of it was tied to ADUHELM. Also note that as of Q2, Eisai's reimbursement for U.S. SG&A costs is now reflected under the collaboration profit sharing line. Collaboration profit sharing in Q2 cut our net operating expenses by $15 million, and that figure includes an $85 million reimbursement from Eisai tied to ADUHELM's commercialization in the U.S. Our effective non-GAAP tax rate for this year's second quarter came in at about 16%, compared with roughly 19% during the same quarter a year ago. Non-GAAP income attributable to noncontrolling interest in Q2 was $84 million, which reflects a $100 million milestone payment to Neurimmune connected to ADUHELM's U.S. launch. Note that Eisai's 45% portion of that milestone was recognized in the collaboration profit sharing line. During Q2, we bought back 1.6 million shares of the company's common stock, spending $450 million. By the end of June 2021 — June 30, to be precise — the repurchase program authorized back in October 2020 still had $3.6 billion remaining. Roughly 150 million shares made up our weighted average diluted count for Q2. For the first quarter, non-GAAP diluted EPS reached $5.68, which is an increase over the $5.34 posted in Q1 of 2021. Cash flow from operations during the second quarter came to about $1.2 billion. We spent $72 million on capital expenditures, and free cash flow was approximately $1.2 billion. When the quarter wrapped up, our debt stood at $7.3 billion, cash and marketable securities at $4 billion, so net debt worked out to $3.3 billion. On top of that, the $1 billion revolving credit facility had no draws against it when the quarter ended. Overall, our financial footing remains quite solid, and we have ample cash and capacity to grow the business over the long haul. Now I'll turn to the revised outlook we're providing for the entire 2021 fiscal year. For full year 2021, we are lifting our revenue forecast. Previously, the range we gave was $10.45 billion to $10.75 billion; our new guidance is $10.65 billion to $10.85 billion. The primary factor behind this is results from our MS franchise that came in above what we anticipated, plus higher royalties from OCREVUS. On non-GAAP diluted EPS, we're keeping guidance at $17.50 to $19, even though we're now including the $125 million upfront payment tied to the InnoCare collaboration we announced recently, which we anticipate incurring in Q3; that payment wasn't factored into our earlier guidance. CapEx guidance stays where it was, at $375 million to $425 million. Our outlook still assumes only modest ADUHELM revenue in 2021, given dosing titration, the time sites need to get ready to diagnose and treat patients, and how long it will take to secure payer coverage; we still expect revenue to begin ramping in 2022 and beyond. We expect TECFIDERA and RITUXAN to keep declining in the U.S., and since those are high-margin products, the resulting revenue drop will weigh on our gross margin percentage. As a reminder, during the second quarter of 2021 our gross margin equaled 83% of revenue, which captures that effect. For the entire year, non-GAAP R&D expenses ought to fall somewhere from $2.45 billion to $2.55 billion; this revised R&D guidance range accounts for the $125 million upfront payment anticipated in the third quarter of 2021, which, as I mentioned, was absent from our earlier guidance. Non-GAAP SG&A expenses for the full year should be somewhere between $2.6 billion and $2.7 billion. The figure we're giving you falls within the same range we laid out before, and it continues to factor in spending of about $600 million on ADUHELM. Out of that total, Eisai would cover around $200 million through reimbursement, and starting April 1 that gets treated as part of collaboration profit sharing instead of showing up under SG&A. Obviously, as the launch progresses, we'll keep a close eye on the pace of our spending. We're still anticipating, as this guidance shows, that R&D and SG&A will both come in larger during the back half of the year compared with the front half, driven by things like the InnoCare collaborations, program readouts and the money we're putting into ADUHELM. Looking ahead, we anticipate tapping into some of the $3.6 billion still available under our share repurchase authorization as the year goes on — though whether we do will hinge on several things, among them what happens with our business development efforts. Our assumption is that currency exchange rates from June 30, 2021, net of hedging activities, will remain in place through the remainder of the year. Guidance does not reflect any possible effects from tax or health care reform, and aside from InnoCare, we've also left out anything that could come from potential acquisitions or major business development deals. So, to close things out: we felt really good about how we performed financially this quarter. Our balance sheet is in excellent shape — plenty of cash on hand, only a small amount of debt, and operations that throw off a lot of free cash. Those strengths, in our view, set us up nicely to keep expanding for years to come. With that, I'll turn it over to Michel for some closing remarks.

Michel Vounatsos

executive
#7

Thanks, Mike. This is a thrilling moment for Biogen, and everything over the next stretch comes down to execution. Our core business across MS, SMA, and biosimilars is doing nicely, showing it can hold up even with competition. Together with Eisai, we have a remarkable chance in front of us. And our entire focus is on operational execution for the worldwide launch of ADUHELM, and we hope before long, lecanemab. We have favorable Phase III results for zuranolone in depression. And we are eagerly waiting for tofersen data in SOD1-ALS. We think a meaningful opportunity to create value lies ahead. We remain firmly behind the clinical data for ADUHELM, which includes the integrity of the approval process. Once more, patient access is our number one priority right now, including for the underserved population and those at greater risk because of ethnicity. And we are receptive to innovative approaches to make sure budgets stay sustainable; to wrap up, I want to express thanks to our employees across the globe who have shown their dedication to making a positive impact on patients' lives, as well as every physician, caregiver, and participant in our clinical development programs. Without their passion and commitment, our ability to deliver medicines to patients could not be achieved. We will now open the call for questions.

Jay Olson

analyst
#8

ADUHELM has honestly had a tough time of it, and we're grateful that you've stuck with us through all of this. From March of 2019 onward, it feels as though Biogen has faced relentless attacks from the press and from other organizations, and those attacks clearly ramped up on June 7, the day ADUHELM won approval. What is it, in your view, about Alzheimer's disease that makes the media respond so harshly to a therapy that might genuinely benefit patients and their families, rather than giving it the same respect they've rightly extended to people affected by other conditions, cancer among them?

Michel Vounatsos

executive
#9

Jay, thank you for those excellent questions. I'll begin, and I imagine Al will chime in afterward. So once more — and what you say in your question, your characterization of what we're up against, is entirely accurate. Yet we aren't the ones bearing the greatest burden. The launch remains in its early stages. This is still just the start; and whatever reasons lie behind the controversy, those who may end up misled, left confused, or refused treatment are the patients. Looking back at what we've learned historically, any advance requires a first step; and we can point to HIV, oncology, or MS, as Al mentioned. Let me take you back to the early 1990s and HIV. The FDA cleared an initial product on the basis of CD4 counts. Enormous controversy followed; afterward came progress around viral loads, and then survival. Since then, roughly 29 products have won approval; and these days, HIV is handled as a chronic illness. That took massive investment in the field. What matters about the biomarker is that it frequently shows up before clinical symptoms appear; and this set of circumstances, this kind of scenario, may well play out identically for AD. Where are the people now who back then fought against approvals for HIV therapies based on biomarkers? The same logic holds for oncology. Al?

Alfred Sandrock

executive
#10

Sure, Jay, I appreciate that question. In my view, the amyloid hypothesis was already a contentious subject well before we ever began work with aducanumab. You had individuals positioned firmly on each side of whether that hypothesis holds up. People had already hardened their positions even prior to the aducanumab data receiving approval. That's somewhat regrettable. A number of these therapies likely never even interacted with the target inside the brain, yet those unfavorable outcomes are treated by us as significant. But here's the key point, Jay: at some stage along this path, the patients were forgotten. We want to steer the discussion back toward the patients. I pointed out the dangers tied to the drug, but equally the dangers tied to delaying aducanumab for the right patients at the right time.

Michael Yee

analyst
#11

Thanks for the remarks, and also for Al's open letter. I appreciate that. Our question concerns the early launch dynamics for ADUHELM. Could you perhaps speak to the 325 sites? How are things going with them? Are they prepared to dose patients? But even more significantly, reimbursement and access. And in particular, whether there's anything you can do with CMS to reach an agreement or something along those lines. Because I believe those are the 2 bottlenecks, or dynamics, that people are going to work through.

Michel Vounatsos

executive
#12

Thank you for the question, Mike. I'll begin, and then Alisha will provide you with far greater detail, since she's nearer to the operation. The background noise and the controversy are regrettable and not helpful, primarily for the patients; and they are confusing. Even so, the team is achieving a great deal, and I'm very proud of their hard work. On the whole, it's somewhat slower than what we assumed, but we are making tremendous progress, with some positives and some headwinds. Alisha?

Alisha Alaimo

executive
#13

Yes, thank you, Michel, and thanks for your question, Michael. Even though we're still at a very early stage in this launch, I'm glad to walk through a handful of key areas we've been tracking that should give some sense of how the environment is taking shape. That said, I have a fair amount of ground to cover, so please stay with me, because I think I need to work through several important topics that I believe will hold real interest for you. Let me begin with the patients. Since launch, physicians have clearly told us there's been a substantial level of interest from patients nationwide—not just among their existing diagnosed patients whom they already know about, but also through referrals of new patients coming from primary care physicians, which is great as well. During our previous call, I mentioned that our team's main priority is giving patients access by helping sites as they develop the capacity and infrastructure needed to treat patients. So sites are only now beginning that initial step in their internal process, which involves finishing their P&T committee reviews. The bulk of Alzheimer's specialists we've spoken with have been remarkably highly engaged with our commercial team and our medical team alike as they get their sites up and running. Several sites have moved more quickly than we expected, which is very good news for us too. And as Michel said at the start, we estimate that 35% of the ready sites have finished a P&T review with a favorable result, or they've told us they don't need that step. As you've surely noticed as well, a few centers have said they won't offer access to ADUHELM at this time. That's disappointing not just for patients, but also for the AD specialists at those centers who had in fact intended to treat their patients with ADUHELM. So our teams are doing everything they can to reach the decision-makers and help them gain a better grasp of the science and the data. The AD specialists and the champions at these sites are also pressing their sites to revisit those decisions. Keep in mind, though, that many of these physicians are still able to prescribe the drug, and they've requested help locating other sites where their patients can be infused. We've also found during this period that patients and their families aren't giving up, and they'll look for new sites when needed, and we're seeing that out in the field as well. Our field teams obviously share that same sense of urgency. And as we've stated publicly too, should any patient be denied access to care, we urge them to reach out to our Biogen support services for assistance, and we will stand behind them. Then, for sites that have gotten a positive P&T committee review or don't need one, there remain multiple steps required to get the complicated patient journey operational. You may have come across some pieces that were published lately. A number of Alzheimer's disease experts have recently stated that standing up this infrastructure so that ADUHELM can be used appropriately is going to take time, resources, and a bit of creative planning. In fact, I just recently went to a number of sites, and what I observed lines up with what we are seeing throughout the whole country. At this moment, sites are working on their protocols. They are reconnecting with their patients. They are weighing or booking amyloid beta confirmation. They are also placing orders for baseline MRIs. After that, they talk over the test results and reach the treatment decision together with their patients. Clearly, this is consuming a fair amount of time. During our previous call with you, we described a program we built alongside LabCorp and Mayo Clinical Labs to assist physicians and patients in getting access to CSF diagnostic laboratory testing. Interest in this program is also proving very strong. In fact, the first orders have already come in for both of our lab partners. As you mentioned, sites are also seeking clarity regarding the reimbursement pathway. CMS's decision to open an NCD analysis will help give sites and health care providers more clarity. Now, while that analysis is in progress, coverage decisions are going to be made by regional Medicare administrative contractors — the MACs, as you know them — along with the Medicare Advantage Plans. Drawing on precedent, our expectation is that the MACs and Medicare Advantage Plans will cover ADUHELM. Now, NCDs for drugs are uncommon, and the sole recent instance of a drug NCD analysis, which was CAR-T, saw both MACs and Medicare Advantage Plans keep covering these — this product throughout the NCA process. We can also confirm that prior authorizations for ADUHELM have already been approved by some Medicare Advantage Plans. As for the MACs, because of the miscellaneous coding, processing the claims does take them a bit of time, but we are likewise aware that claims have already reached the MACs. So while the NCD analysis is happening, we are actively collaborating with sites to back patient access and reimbursement. Bear in mind, and as I saw at the various sites I went to, every site will operationalize at its own pace, which explains why patient infusions will ramp up gradually across the year, as we have mentioned. Even though this process will take time, it was truly humbling to witness just how much effort and passion these physicians are pouring into creating the infrastructure to treat their patients; and I feel really proud of how diligently our teams are working to help these sites as they break new ground. Our teams remain focused, though, Michael. We have a job to do on behalf of the AD community, and we will not be distracted from that mission regardless of what we see.

Umer Raffat

analyst
#14

I'd like to split my focus on Alzheimer's into 2 parts. First, I'm aware there's been plenty of talk about an early filing for donanemab. And it puzzles me somewhat that there's been no commentary at all about a possible early filing for BAN2401. And I understand Eisai takes the lead on regulatory matters, but I also recognize that you folks sit on the Steering Committee. So in 2021, should we be expecting a BAN2401 filing? And second, Alisha, just to be clear. Regarding the $1.6 million in aducanumab sales during the second quarter, what portion of that came from inventory? Because that sales figure suggests roughly 3,000 patients were on the drug in June. Is that accurate?

Mike McDonnell

executive
#15

Yes. I mean, I'll handle that second part; this is Mike speaking. Umer, thanks for asking. And then Al will take the second one. I mean, we usually don't delve too deep into kind of the channel dynamics; but it's early days; we don't really have clear visibility into patient metrics for a drug like ADUHELM; it's very early days. And obviously, we're pleased to see that we completed some shipments, and we got the $1.6 million in sales done. But as those make their way out to sites and turn into patient treatment, we'll have more to say about how much sits in the channel and how much is actually in — going into patient treatment.

Michel Vounatsos

executive
#16

There's still more to share about that, but it's safe to figure that given we only had 2 weeks, a large portion of it is essentially a channel. AL?

Alfred Sandrock

executive
#17

Right. Umer, as you're aware, it's not our practice to discuss what happens in our conversations with regulators. Still, we view it as quite an encouraging signal that lucanimab received breakthrough therapy designation. And I'm confident that my colleagues at Eisai and Biogen will do all that's possible to speed things along on the regulatory side.

Michel Vounatsos

executive
#18

Also, I want to mention how encouraging it is to see other drugs that work through that identical pathway — this kind of class effect that faces so many doubts. From Biogen's standpoint, we are glad to see newcomers arrive, whether they turn out to be rivals or collaborators; the clinician benefits either way. By definition, the patient benefits too.

Marc Goodman

analyst
#19

Could you walk us through how this NCD process works? What possible outcomes exist? And please explain what would happen in a negative scenario. What would count as a negative scenario? And what options would you have if that occurred?

Alisha Alaimo

executive
#20

Thanks for asking, Marc. I'll take that one. It's still too early in this process to predict how this NCD analysis will turn out, but I can share some inputs so everyone understands there are 5 possible scenarios at <<inaudible>>. First, there's a decision of no coverage. Although that's theoretically possible, over the last 15 years, no FDA-approved drugs have gone uncovered. I think that's worth knowing. Second, coverage could go to indication, essentially the label. Third, coverage might come with restrictions — perhaps limiting it to a specific patient population, or restricting prescribing to certain specialists, with those specialists defined by them. Fourth, coverage could come with evidence development. And finally, it could be left to the MAX's discretion. Importantly, after a national coverage decision is issued, every MAX and Med Advantage Plan has to follow the NCD. That means the NCD supersedes any local or Medicare Advantage plan currently in place; this is why we think the NCD will bring about more consistent access and clearer reimbursement expectations, which is genuinely beneficial for all, since one question people have had is whether this will be reimbursed. That said, if the outcome turned out negative — though we can't predict that — naturally, in Biogen's true form, we'd want to discuss it and explore what other outcome might be possible, depending on whatever additional data they may require.

Michel Vounatsos

executive
#21

Thanks, Alisha.

Matthew Harrison

analyst
#22

Wonderful. I was hoping you might be able to share a bit more regarding the reimbursement dynamics you're currently observing. And perhaps in particular, could you say whether you know of anybody infused with commercial drug early in June, and whether a MAC has actually paid them or not.

Alisha Alaimo

executive
#23

Yeah. So Matthew, thank you for asking. And sadly, I would really like to provide you with that answer. But since it's early days and since claims processing takes a fair amount of time, sadly, I'm not able to give you feedback on it at this point, because that process is still underway. So as I mentioned earlier, I'm aware that the Medicare Advantage Plans have approved the prior authorizations, which in fact is a positive thing that those are in place, since it does give sites some reassurance that reimbursement will come; but regarding the MAX, we know they do have claims, yet since it's under miscellaneous coding, it does take some time. So I would really like to provide that answer, but right now we simply don't have it.

Phil Nadeau

analyst
#24

Alisha, when you were speaking and in your reply to Michael, you said many of the centers are arranging — verification that beta amyloid is present in patients. I'd like to know the reason for that. Are they choosing on their own to find those patients or verify them? Or is it that Medicare Advantage or the MAX is imposing the diagnostic requirements?

Alisha Alaimo

executive
#25

All right. I appreciate that question too; and from the time of PDUFA, we've kept hearing a strong degree of interest in our ABC program, which I discussed earlier, meaning the CSF testing, which you heard me mention when I gave my first answer. The reason such interest exists comes mainly from 3 reasons. First, a steady message reaches us from the AD experts and the clinicians that their selection of patients will be matched to the population studied in our clinical trials. Thus, 100% of patients in our clinical development program had amyloid plaques confirmed. Still, you should also realize that nobody has actually issued a policy as of yet. So I cannot honestly say a mandate exists regarding amyloid beta confirmation, but our expectation is that perhaps those will appear in the policies. Second, no reimbursed test exists right now for confirming amyloid presence, and this program that we provide serves as a solution giving access to patients who otherwise would not have the means to pay for this lab test, much less the expense of a PET scan. And as you're aware, for PET scanning, third, several regions of the country remain, especially the Mountain West, Hawaii and Alaska, where amyloid PET access isn't available because of how radiopharmacies are distributed and the short half-life of the radio ligand. But I also mentioned on an earlier call that we truly need both PET and CSF. And we've observed these orders arriving for both of our lab partners; and we continue working diligently with a coalition to determine whether we can secure pet reimbursement through CMS.

Paul Matteis

analyst
#26

I'd like to know what kind of liability a doctor takes on by writing a prescription for aducanumab before an NCD exists. Say, for instance, the medication goes to someone who ultimately isn't covered by an NCD, or who doesn't meet some set of — prior off isn't quite the term, but something like prior criteria for picking patients — could the treatment center end up owing Medicare a refund? And do you believe that might slow uptake, given this sort of wider uncertainty about financial exposure?

Alisha Alaimo

executive
#27

I'll take that one. I'd call it a really perceptive question, since this is exactly where a great deal of the anxiety originates, I think, among the centers — they're asking whether reimbursement will come through. The response is that you won't find out unless you attempt it, which is why centers are beginning to submit their claims now and observe how those get handled. That said, once an NCD is issued, clearly CMS will at that moment also need to determine how to handle those patients should they turn out not to meet the NCD criteria. So sadly, we won't have an answer until that whole process reaches its conclusion.

Michel Vounatsos

executive
#28

If we take a broader view, I'd say this kind of muddle is something we've witnessed throughout. Back when SPINRAZA came to market, that same muddle existed. Plus, the controversy isn't helping bring any clarity—it's causing people to feel more fear; even so, we're starting to observe movement in a positive direction. This marks the start of a process. We remain in the early days.

Cory Kasimov

analyst
#29

I'd like to dig a bit deeper into a few of those market stats you went over. Could you share the count of P&T reviews that are still pending, and perhaps even more useful, what share of them returned unfavorable results? Also, when big, influential institutions such as the Cleveland Clinic put out public remarks, does that carry any meaningful weight for the smaller community-style clinics you've brought on board — possibly shaping how they prescribe early on?

Michel Vounatsos

executive
#30

Alisha?

Alisha Alaimo

executive
#31

Yes. All right, Cory, thanks for asking that. Regarding the P&T committee, the figure we provided — 35% — is really the sole statistic I'm able to share right now. And that figure shifts every single day, correct? So reviews by P&T committees are taking place all over the country. Naturally, we know about the truly major ones that get publicized. But some of the smaller ones at our targeted sites happen daily, so an exact number isn't something I can genuinely give. As for the second part of what you asked, I'm unable to speak to how decisions get made at particular sites. That said, I will share that we feel let down that sites specializing in Alzheimer's disease have said they won't offer access to ADUHELM at this time; that's disappointing not just for patients, but naturally also for the 80 specialists working at those sites. Every site follows its own particular process and has its own decision makers, so no single explanation really exists. And even the reasons you may read about publicly differ somewhat from what we hear firsthand, which, once more, creates added confusion in the marketplace. And just so you're aware, we're doing everything possible to get before these decision makers so they can better grasp the science and the data. Furthermore, specialists and champions at these sites have stepped forward to see whether they might revisit their existing policy. But keep in mind that plenty of physicians are still able to prescribe the product and have requested help locating alternative sites in order to infuse their patients. Having said that, other sites will be watching these accounts to observe what sorts of policies and procedures they implement based on how they make decisions. Still, when all is said and done, these accounts have likewise stated it's only for now. And there could be a possible chance to have them revisit that quite soon.

Michel Vounatsos

executive
#32

Right. I'd simply like to back up the points Alisha made. I also got the chance to speak with quite a few clinicians and scientific leaders, among them people from a few of the centers that turned us down. This is just the start of a process. On top of that, I believe we bear a responsibility to supply additional data, as AL mentioned, and that work is underway right now. Keep in mind that within AD, EMBARK holds our most extensive database.

Alfred Sandrock

executive
#33

Let me also jump in briefly on that point — when 35% have finished a P&T review either with a favorable result or have said they won't need one, you shouldn't take that to mean the other 65% came back unfavorably. Things are still quite early, and most of those are yet to be resolved.

Terence Flynn

analyst
#34

Thanks. Alisha, I was hoping you might go into more detail about one of those possible NCD situations you brought up — the coverage with evidence development one. Basically, how would that function if there were a demand for extra clinical work? And during that period, would the drug be paid for while that extra clinical work is being done, or would there be no coverage for the drug in that interim stretch? I think people are somewhat unclear about how the CED process works.

Alisha Alaimo

executive
#35

Yeah, that's a really good question. And clearly, we've examined this too. And sadly, a CED result can come in so many varieties. You might get something as limiting as permitting reimbursement for just 500 patients in this clinical trial, all the way to any patient being able to receive reimbursement provided they meet a criteria so we can gather evidence. So I wish I could give you a straight answer, but we're at such an early stage. We don't know what the result will turn out to be, yet a CED can come in a great many shapes.

Michel Vounatsos

executive
#36

There's one more thing Chirfi wants to mention.

Chirfi Guindo

executive
#37

Right. Let me give you a bit more context here. A CED existed for the PET process. When it came to the first study — that initial IDEA study, which ran enrollment for roughly 2 years — somewhere around 16,000 patients were signed up across 2016 to 2018. Executing it was quite hard, almost like running a clinical trial. And CMS itself acknowledged one of the difficulties: minorities made up only 4% of that representation. So CED certainly comes with its share of problems. That's why, as our engagement continues, we'll be pushing to ensure that should a CED be the route, access for diverse patient populations isn't really limited by it.

Michel Vounatsos

executive
#38

All right. So we now have something that has never happened before: an FDA accelerated approval for a product treating Alzheimer's disease, and it rests on unambiguous evidence demonstrating a decrease in amyloinebetaplaque — something reasonably likely to serve as a predictor of clinical benefit, and here, a lessening of clinical decline. So can we, without delay, redirect our focus toward the patients who need this, in the same manner we once did with HIV and with oncology? I appreciate everyone being here with us today.

Operator

operator
#39

This concludes today's call. Thank you for your participation. You may now disconnect.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Biogen Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Biogen Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Biogen Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.